• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Study finds tramadol effects vary among patients

Video

“Tramadol is a mixed-class medication and it has weak opioid agonist activity. Normally, we consider that a safer option compared to other opioids, but it's actually a pro drug, so it has to be metabolized to have an effect,” says Sarah F. Faris, MD.

In this video, Sarah F. Faris, MD, discusses the findings of the Urology study, “Persistent Opioid Usage After Urologic Intervention and the Impact of Tramadol,” and how tramadol can have varying impacts on patients after urologic intervention. Faris is an associate professor of surgery at the University of Chicago, Illinois.

Related Videos
Samuel L. Washington III, MD, MAS, answers a question during a Zoom video interview
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Leo Dreyfuss, MD, answers a question during a Zoom video interview
Conceptual image for prostate cancer treatment | © Dr_Microbe - stock.adobe.com
David Gilbert answers a question during a Zoom video interview
Female doctor talking with male patient | Image Credit: © Prostock-studio - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.